Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis reports positive phase III data for RMS drug

Sanofi-aventis reports positive phase III data for RMS drug

18th October 2010

Sanofi-aventis has published new clinical trial data which supports the efficacy of a new treatment for relapsing multiple sclerosis (RMS).

The company conducted a two-year phase III study of teriflunomide, an investigational oral disease modifier, in order to gauge its effectiveness in reducing relapses when compared to placebo.

It was found that the drug was able to cut annualised relapse rates by 31 per cent, while demonstrating encouraging performance in terms of reducing the risk of disability progression and brain disease activity.

These represent the first findings from a planned large-scale phase III study programme assessing teriflunomide, following on from positive results in phase II trials.

Marc Cluzel, executive vice-president of research and development at Sanofi-aventis, said: "These exciting results with teriflunomide represent a real new hope to delivering an oral therapy to patients who live with this serious condition and are eager for new treatment options."

Earlier this month, the company published clinical trial data on a new compound called BSI-201, demonstrating its efficacy as a breast cancer therapy.ADNFCR-8000103-ID-800120742-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.